Relationship of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) pharmacokinetics of uptake, distribution, and tissue/plasma partitioning in rat organs and intracerebral tumors

• Published in: Cancer chemotherapy and pharmacology 1978, Vol.1 (4), p.233-242
• Main Authors: Levin, V A, Kabra, P A, Freeman-Dove, M A
• Format: Article
• Language: English
• Subjects: Animals; Brain Neoplasms - metabolism; Carmustine - blood; Carmustine - metabolism; DNA - metabolism; Kinetics; Lomustine - blood; Lomustine - metabolism; Male; Neoplasm Proteins - metabolism; Nitrosourea Compounds - metabolism; Protein Binding; Rats; Rats, Inbred F344; RNA - metabolism; Tissue Distribution
• ISSN: 0344-5704; 1432-0843
• DOI: 10.1007/BF00257156

To obtain a clearer definition of the relationship between the structure of BCNU and CCNU and their antitumor activity, we determined the uptake, distribution, and tissue/plasma partition ratios of both compounds in normal organs and intracerebral (ic) 9L tumors in rats. Greater uptake, distribution, and tissue/plasma partition ratios were obtained for parent CCNU in fat, liver, and brain, and for parent BCNU in kidney. CCNU distributes more rapidly and extensively than BCNU only in fatty tissues. BCNU distributed more extensively in kidney and liver. Rats received bolus IV injections of 14C-labeled BCNU or CCNU in increasing doses; measurements taken 30 min after injection showed that three- to fourfold more BCNU than CCNU was bound to nucleic acids in brain and ic 9L tumor tissue. Because the chloroethyl group is the alkylating moiety for both drugs, these findings implied that BCNU biotransformed to its reactive intermediate more rapidly than did CCNU. These observations, together with previous findings, indicate that one reason for the greater effectiveness of BCNU than CCNU against ic 9L tumors is its superior ability to form an intermediate that can bind to ic 9L tumor cell nucleic acids.